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Under the principles of evidence-based medicine, clinical trials are the epitome of primary comparative 
research on humans and form the basis for deciding which treatment might work best for a specific patient 
problem. Randomisation of patients into groups to be compared is crucial in ensuring similarity of the groups 
for any known or unknown confounders, so that any difference seen at the trial’s end can be directly 
attributed to the administered intervention. Allocation concealment and blinding of all entities involved in a 
trial (patients, orthodontists, and outcome assessors) helps minimising selection, performance, and 
detection bias and further enhances the robustness of the scientific procedure. Finally, pre-registration of 
the full trial protocol helps in having transparency throughout the research process and minimises the risk 
of publication bias by making trial traceable from the start. However, sometimes even well-designed clinical 
trials cannot always fully answer a clinical research hypothesis.  
 
Shortcomings of clinical trials 
Planning, conducting, and monitoring a clinical trial is an arduous task and considerable time, effort, and 
money is required to recruit, treat, and then follow the included patients throughout the trial. As a result, 
clinical trials often include much smaller patient samples than non-randomised studies, due to the increased 
costs. Indeed, such often called ‘pilot’ trials with very small sample sizes are unfortunately very prevalent in 
orthodontic literature and can include as little as 10 patients, while almost 20% of trials include less than 30 
patients (re-analysed from Al-Mohrabi et al. 2018). This hampers the power of clinical trials to identify an 
existing difference between two treatments and affects the precision of their estimates. This has been 
illustrated by data indicating that initial small trials with statistically significant findings are later on refuted 
by subsequent larger trials (Cappelleri et al. 1996; Ioannidis, 2005). Furthermore, issues in the conduct or 
reporting of clinical trials can introduce bias or limit the useful information that can be extracted from a trial 
report (Bearn and Alharbi, 2015; Papageorgiou et al. 2015; Koletsi et al. 2016; Papageorgiou et al. 2018). 
Additionally, the results of each single clinical trial can be directly applicable only to populations similar to 
the patients included in the trial and might not be safely transferable to other patients. Generalisability of a 
trial’s results can therefore only be attained by setting multiple trial centres that cover diverse patient groups 
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or by synthesising multiple clinical trials. This enables to have a wider range of patients and clinical settings, 
thereby introducing the clinical variation that is seen in clinical reality. 
 
Evidence synthesis from multiple trials 
Synthesis of data from multiple clinical trials is properly done by performing meta-analyses within the 
framework of a systematic review of existing literature, as this enables a transparent and mostly objective 
format to identify and combine the entirety of existing primary research around a scientific question. The 
main strengths of meta-analysis include combining data on a treatment’s clinical performance to a single 
estimate with increased statistical power, illustrating the clinical heterogeneity that might be expected in 
clinical situations, and assessing the influence of patient-, treatment-, or study-related characteristics on the 
treatment’s performance. Sometimes meta-analyses might even be able to shed light on novel research 
questions that were not raised in the included original primary trials. They also provide balanced and 
transparent evidence for patients, relatives, and policymakers about the benefits / harms of interventions 
and they can be the starting point for trustworthy clinical practice guidelines (Guyatt et al 2008). However, 
systematic reviews and meta-analyses are a form of secondary research, which means they are 
encumbered by the existence of well-designed primary clinical trials to fuel evidence-based 
recommendations. Additionally, the credibility of a meta-analysis is dependent on both the scientific rigor 
(the ‘risk of bias’) of included primary trials and on the robustness of the systematic review / meta-analysis 
methods used to combine these trials (Papageorgiou 2014). This means that meta-analysis has potentially 
double the risk of bias compared to primary studies, while at the same time meta-analysis of flawed studies 
only leads to flawed or potentially misleading pooled estimates. In a way, meta-analysis might be compared 
to a wall or a building, whereas single trials are the single building blocks used to construct this. The stability 
of the construct is only secured by solid building blocks that interlock well, whereas flawed primary trials 
lead to meta-analysis of questionable stability / credibility. Adding to that, meta-analyses rely on the 
reporting completeness of randomized trials’ papers, which has been shown to be often problematic (Bearn 
and Alharbi, 2015) and can limit the meta-analyses. Overall, the quality of systematic reviews or meta-
analyses might be hampered by many factors, including risk of bias, indirectness, imprecision, 
inconsistency, and publication bias, which can affect the validity of their findings (Guyatt et al 2008). 
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Published randomised trials and systematic reviews in orthodontics 
Notwithstanding this, systematic reviews and meta-analyses are becoming increasingly popular in 
orthodontic literature and lately more systematic reviews / meta-analyses than randomised trials are 
published each year (Table 1; Figure 1). This trend might be explained by many factors. 
First, systematic reviews require on average less resources than clinical trials (Glasziou et al. 2006) 
and might be completed within a shorter timeframe—whereas a randomised trial of comprehensive 
orthodontic treatment might take many years. Second, systematic reviews might be on average ‘cheaper’ 
than clinical trials, but receive equal, if not more, citations than randomised trials and other study designs 
(Patsopoulos et al. 2005). Third, systematic reviews do not per se involve any procedures on human patients 
and do not require ethical clearance beforehand (Greene and Bearn 2013), which makes it a popular 
research project for postgraduate students or junior researchers. Finally, many journals or funding agencies 
ask that any new large clinical trial on a field should begin and end with a systematic review of existing 
literature to help put the trial’s results into context (Clarke et al. 2010). In such cases, systematic reviews 
are justified as they help reduce research waste originating from unjustified research and might minimise 
burden or adverse effects in patients allocated to relatively less effective treatments in new trials (Chalmers 
et al. 2014). 
There is however something amiss when disproportionately more secondary research is conducted 
on the expense of primary research. For one, treatment techniques and philosophies constantly evolve with 
increasingly accumulated evidence and experience, while novel materials and appliances are constantly 
marketed. If clinical trials do not keep up with recent developments, then researchers and clinicians alike 
run the risk of falling behind the times (Seehra et al. 2017), which might translate to novel treatments being 
used on patients without prior knowledge about their efficacy or safety. Additionally, recycling already 
existing clinical trials in new systematic reviews with overlapping meta-analyses provides no additional new 
information and can be regarded as research waste in terms of unnecessarily spent resources. Some 
overlap between meta-analyses might be desirable for either replication purposes or to correct the record 
set by an initially misleading meta-analysis due to biased use of eligibility criteria, outcome definitions, 
analyses, or interpretation of results. Also, updating the evidence provided by an older meta-analysis is 
another valid reason to perform a new meta-analysis on the subject (Garner et al. 2016), but should ideally 
be preceded by documented publication of a minimum number of new and meaningful clinical trials. 
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Importantly, there may be less noble incentives for doing another redundant systematic review, as industry-
sponsored systematic reviews conducted by contractors might be used as a particularly powerful marketing 
tool (Ioannidis, 2016). Therefore, careful examination of sponsoring, conflicts of interests, and transparency 
of the report is a crucial, yet often overlooked, aspect of a study’s critical appraisal. 
 
Summary and recommendations 
Systematic reviews and meta-analyses have the potential to play an important role in evidence-based 
decision-making by collating and appraising all existing clinical trials pertaining to a specific question. They 
need however to be both true and useful to clinicians and researchers alike, which means that reviewers 
should go at great lengths to minimise bias and research waste by. To this end, there are several steps that 
researchers or editors and peer-reviewers of scientific journals can take. As a minimum, researchers 
planning on undertaking a systematic review should have in-depth knowledge of the field they wish to cover 
and be aware of most primary studies and systematic reviews existing in the field. Prior to registering the 
protocol of their systematic review in PROSPERO (Sideri et al. 2017) the authors should ensure that the 
research question has not been previously addressed in another review or that an adequate number of trials 
have been published since the last review to justify its update. As far as proper methodology for systematic 
reviews or meta-analyses are concerned, detailed guidance can be found in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins and Green, 2011). Furthermore, as with any type of research, 
transparency in terms of both sponsorship or conflicts of interest, as well as open data sharing 
(Papageorgiou and Cobourne, 2018) is of paramount importance in building trust on systematic reviews. 
Finally, peer-reviewers and editors of orthodontic journals need to be aware of the massive production of 
systematic reviews and ensure that these are indeed carefully conducted and useful additions to the existing 
literature. Just as a novel badly-conducted systematic review of previously unassessed trials might mislead 
readers, so is a well-designed duplicate systematic review of previously covered trials equally unfit for 
publication. Critical appraisal and watchful monitoring of the systematic reviews that manage to get publish 
will be useful in both improving the quality of existing evidence in orthodontics and – hopefully – encourage 





Al-Moghrabi D, Tsichlaki A, Pandis N, Fleming PS. Collaboration in orthodontic clinical trials: prevalence 
and association with sample size and funding. Prog Orthod. 2018 Jun 11;19(1):16. 
Cappelleri JC, Ioannidis JP, Schmid CH, de Ferranti SD, Aubert M, Chalmers TC, Lau J. Large trials vs 
meta-analysis of smaller trials: how do their results compare? JAMA. 1996 Oct 23-30;276(16):1332-8. 
Ioannidis JP. The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and 
Meta-analyses. Milbank Q. 2016 Sep;94(3):485-514. 
Bearn DR, Alharbi F. Reporting of clinical trials in the orthodontic literature from 2008 to 2012: observational 
study of published reports in four major journals. J Orthod. 2015 Sep;42(3):186-91. 
Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JP, 
Oliver S. How to increase value and reduce waste when research priorities are set. Lancet. 2014 Jan 
11;383(9912):156-65. 
Clarke M, Hopewell S, Chalmers I. Clinical trials should begin and end with systematic reviews of relevant 
evidence: 12 years and waiting. Lancet. 2010 Jul 3;376(9734):20-1.  
Garner P, Hopewell S, Chandler J, MacLehose H, Schünemann HJ, Akl EA, Beyene J, Chang S, Churchill 
R, Dearness K, Guyatt G, Lefebvre C, Liles B, Marshall R, Martínez García L, Mavergames C, Nasser 
M, Qaseem A, Sampson M, Soares-Weiser K, Takwoingi Y, Thabane L, Trivella M, Tugwell P, Welsh 
E, Wilson EC, Schünemann HJ; Panel for updating guidance for systematic reviews (PUGs). When 
and how to update systematic reviews: consensus and checklist. BMJ. 2016 Jul 20;354:i3507. 
Glasziou P, Djulbegovic B, Burls A. Are systematic reviews more cost-effective than randomised trials? 
Lancet. 2006 Jun 24;367(9528):2057-8. 
Greene LE, Bearn DR. Setting up a randomized clinical trial in the UK: approvals and process. J Orthod. 
2013 Jun;40(2):104-11. 
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: 
an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–
926. 
Higgins JPT, Green S. 2011. Cochrane handbook for systematic reviews of interventions 5.1.0 (updated 
2011 Mar); [accessed 2018 February 5]. http://handbook-5-1.cochrane.org/ 
7 
Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005 Jul 
13;294(2):218-28. 
Koletsi D, Spineli LM, Lempesi E, Pandis N. Risk of bias and magnitude of effect in orthodontic randomized 
controlled trials: a meta-epidemiological review. Eur J Orthod. 2016 Jun;38(3):308-12. 
Papageorgiou SN, Cobourne MT. Data sharing in orthodontic research. J Orthod. 2018 Mar;45(1):1-3. 
Papageorgiou SN, Xavier GM, Cobourne MT, Eliades T. Registered trials report less beneficial treatment 
effects than unregistered ones: a meta-epidemiological study in orthodontics. J Clin Epidemiol. 2018 
Aug;100:44-52. 
Papageorgiou SN, Xavier GM, Cobourne MT. Basic study design influences the results of orthodontic 
clinical investigations. J Clin Epidemiol. 2015 Dec;68(12):1512-22. 
Papageorgiou SN. Meta-analysis for orthodontists: Part II--Is all that glitters gold? J Orthod. 2014 
Dec;41(4):327-36. 
Patsopoulos NA, Analatos AA, Ioannidis JP. Relative citation impact of various study designs in the health 
sciences. JAMA. 2005 May 18;293(19):2362-6. 
Seehra J, Pandis N, Fleming PS. Clinical evaluation of marketed orthodontic products: are researchers 
behind the times? A meta-epidemiological study. Prog Orthod. 2017 Dec;18(1):14.  
Sideri S, Papageorgiou SN, Eliades T. Are orthodontic systematic reviews registered a priori in 




Figure 1. % part of total publications in each year comprising of Randomised Clinical Trials (RCTs) or 
Systematic Reviews / Meta-Analyses (SRs/Mas). Data exported using the corresponding filters in MEDLINE 




Table 1. Number of publications listed in MEDLINE (through PubMed) each year using the simple search 
orthodont* and selecting PubMed’s filters for randomised trials or systematic reviews / meta-analyses. 












2007 1724  78 4.5%  16 0.9% 
2008 1855  78 4.2%  19 1.0% 
2009 1919  88 4.6%  21 1.1% 
2010 2036  101 5.0%  36 1.8% 
2011 2122  102 4.8%  32 1.5% 
2012 2434  108 4.4%  35 1.4% 
2013 2615  97 3.7%  67 2.6% 
2014 3079  99 3.2%  74 2.4% 
2015 3466  102 2.9%  119 3.4% 
2016 3302  136 4.1%  134 4.1% 
2017 3307  99 3.0%  149 4.5% 
MA, meta-analysis; RCT, randomised clinical trial; SR, systematic review. 
 
 
